NCT04808245
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04808245
Title A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated Gliomas (INTERCEPT-H3)
Acronym INTERCEPT-H3
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors German Cancer Research Center
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU

Facility Status City State Zip Country Details
Department of Neurology and Polyclinic, Universitiy Clinic Heidelberg Heidelberg Baden-Wurttemberg 69120 Germany Details
University Medical Center Mannheim, Department of Neurology Mannheim Baden-Wurttemberg 68167 Germany Details
University Clinic Tuebingen, Neurological Clinic, Department of Neurology Tübingen Baden-Wurttemberg 72076 Germany Details
Dr. Senckenberg Institute for Neurooncology, University Hospital Frankfurt Frankfurt am Main Hesse 60528 Germany Details
Clinical Neuro-Oncology Section, University Hospital Bonn (UKB) Bonn North Rhine-Westphalia 53127 Germany Details
Neurooncology Department, University Hospital Essen Essen North Rhine-Westphalia 45147 Germany Details
Clinic and Polyclinic for Neurosurgery, University Hospital Carl Gustav Carus Dresden Dresden Saxony 1307 Germany Details
Department of Neurosurgery with Pediatric Neurosurgery Berlin State of Berlin 10117 Germany Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field